Clinical trials: Locally Advanced /Metastatic Solid Tumors, open to volunteers
TMB-H, Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
The goal of this clinical trial is to determine the efficacy of IMC-001 in metastatic or locally advanced TMB-H solid tumor patients.
- Trial name
- TMB-H (NCT06365840)
- Testing
- IMC-001
- Where
- 4 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- ImmuneOncia Therapeutics Inc.
Advanced Solid Cancer, Metastatic Solid Tumor
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 as monotherapy in adult patients with advanced solid tumors
- Conditions
- Advanced Solid Cancer, Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer
- Trial name
- NCT06666270
- Testing
- SYN818
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
A phase I/II study to examine the safety, tolerability, pharmacokinetics and efficacy of XZP-5955 tablets in patients with advanced solid tumors harboring NTRK or ROS1 gene fusion
- Trial name
- NCT04996121
- Testing
- XZP-5955 tablets
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Solid Tumor, Non-Small Cell Lung Cancer
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma
- Trial name
- NCT04198766
- Testing
- INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg
- Where
- 60 sites in United States, Singapore and 2 more
- Volunteers
- 340 people
- Sponsor
- Inhibrx Biosciences, Inc
Advanced Solid Tumor
A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
In Phase I, This study will explore the tolerability and safety of RC118 in patients with locally advanced unresectable or metastatic malignant solid tumors with positive Claudin 18.2 expression, and determine the maximum…
- Trial name
- NCT05205850
- Testing
- RC118-ADC
- Where
- 2 sites in China
- Volunteers
- 135 people
- Sponsor
- RemeGen Co., Ltd.
Urothelial Carcinoma, Solid Tumor
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
This phase II study is designed to explore the efficacy and safety of SI-B003 monotherapy and BL-B01D1+SI-B003 combination therapy in patients with locally advanced or metastatic urothelial carcinoma and other solid tumors.
- Trial name
- NCT05965856
- Testing
- BL-B01D1, SI-B003
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumor Cancer
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase…
- Trial name
- NCT04777994
- Testing
- ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Death-1 (PD-1) Inhibitor
- Where
- 30 sites in United States, France and 4 more
- Volunteers
- 248 people
- Sponsor
- Calico Life Sciences LLC
Head and Neck Squamous Cell Carcinoma, Solid Tumor
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
This study is an open, multicenter, non-randomized Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M24D1 in patients with locally advanced or metastatic…
- Trial name
- NCT07232524
- Testing
- BL-M24D1
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Locally Advanced or Metastatic Solid Tumor
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-B01D1.
- Trial name
- NCT05194982
- Testing
- BL-B01D1
- Where
- 8 sites in China
- Volunteers
- 570 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma
- Trial name
- NCT06799065
- Testing
- ATX-295, ATX-295 and bevacizumab (or biosimilar)
- Where
- 11 sites in United States
- Volunteers
- 218 people
- Sponsor
- Accent Therapeutics
Solid Tumors
REC-7735 in Participants With Solid Tumors
The study is designed to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of REC-7735 in participants with unresectable, locally advanced, or metastatic…
- Trial name
- NCT07819136
- Testing
- REC-7735
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- Recursion Pharmaceuticals Inc.
Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC)
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
This study will recruit patients with the following cancer indications: ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer, with inoperable locally advanced or metastatic solid tumours.
- Conditions
- Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC), Synovial Sarcomas, Head and Neck Cancer
- Trial name
- NCT07613723
- Testing
- ZI-MA4-1 (TCR-NK cells), Cyclophosphamide, Fludarabine
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people
- Sponsor
- Zelluna Immunotherapy AS
Non Small Cell Lung Cancer, Cervical Cancer
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab.
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT07218003
- Testing
- RNDO-564, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 149 people
- Sponsor
- Rondo Therapeutics
Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm
Adoption of Audio Recording in the Outpatient Supportive Care Center
This study evaluates how patients feel about having an audio recording of their visit to help remember information given to them and share that information with family members and/or caregivers not present during a clinic visit.
- Conditions
- Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04871477
- Testing
- Communication Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced / Metastatic Solid Tumors
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with…
- Trial name
- ASCEND (NCT07335497)
- Testing
- CR-001, Paclitaxel, trifluridine and tipiracil
- Where
- 34 sites in United States, Australia and 7 more
- Volunteers
- 540 people
- Sponsor
- Crescent Biopharma, Inc.
Ovarian Cancer, Pancreas Cancer
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma.
- Conditions
- Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
- Trial name
- NCT06582017
- Testing
- QXL138AM Injection every 2 weeks by IV Infusion
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nammi Therapeutics Inc
Cancer, Colorectal Cancer
FOG-001 in Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
- Conditions
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
- Trial name
- NCT05919264
- Testing
- FOG-001, mFOLFOX-6, Nivolumab
- Where
- 33 sites in United States, Australia
- Volunteers
- 619 people
- Sponsor
- Parabilis Medicines, Inc.
Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid…
- Conditions
- Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT07503808
- Testing
- IDE034
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- IDEAYA Biosciences
Solid Tumor, Adult, Mesothelioma
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or…
- Conditions
- Solid Tumor, Adult, Mesothelioma, NSCLC
- Trial name
- NCT04665206
- Testing
- VT3989, Nivolumab & Ipilimumab, Osimertinib
- Where
- 12 sites in United States, Australia
- Volunteers
- 434 people
- Sponsor
- Vivace Therapeutics, Inc
Solid Tumor
A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors
The goal of this clinical trial is to test in patients with local advanced/metastatic solid tumors. the main questions it aims to answer are: to assess the safety and tolerability of BB-1709.
- Trial name
- NCT06241898
- Testing
- BB-1709
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Bliss Biopharmaceutical (Hangzhou) Co., Ltd